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Abstract 
In this study, three novel series of benzoxazinone, benzothiopyranone and benzopyranone 
derivatives were designed and synthesized through scaffold morphing from benzothiazinones 
targeting DprE1. All compounds were evaluated for their in vitro activities against 
Mycobacterium tuberculosis (M. tuberculosis) and cytotoxicity against Vero cell line. Among 
the three series, the benzothiopyranone series displayed excellent antimycobacterial activity 
and low cytotoxicity. Compound 6b exhibited potent in vitro activity against both 
drug-susceptible and drug-resistant M. tuberculosis clinical strains with MICs < 0.016 
μg/mL. In addition, compound 6b demonstrated excellent ADME/T and PK properties and 
potent in vivo efficacy with bactericidal activity comparable to human equivalent dose of 
isoniazid (INH) in an acute mouse model of TB. Compound 6b which exhibits good 
inhibitory activity against DprE1 is under evaluation as a potential drug candidate for the 
treatment of tuberculosis. The current study provided new insight into the structural and 
pharmacological requirements for DprE1 inhibitors as potent antitubercular agents. 
Keywords 
Benzothiopyranones; drug-resistant M. tuberculosis; ADME/T; DprE1 inhibitors; 
antitubercular agents 
1. Introduction 
  Tuberculosis (TB) continues to be a major global health problem with millions of new 
cases every year. In a 2017 global TB report, TB was the ninth leading cause of death 
worldwide, and for the past five years (2012-2016) had been the leading cause of death from 
a single infectious agent, ranking above HIV/AIDS [1]. The prevalence of multidrug-resistant 
TB (MDR-TB) and extensively drug resistant TB (XDR-TB) has created a renewed demand 
for the discovery and development of novel TB drugs to improve the treatment outcomes. 
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Due to the high attrition rate in new drug development, the need for safer and more effective 
agents with novel mechanisms of action for the treatment of TB cannot be overemphasized 
[2].  
The evaluation of novel chemical scaffolds possessing desirable pharmacological profiles 
against M. tuberculosis and the identification of novel drug targets on M. tuberculosis are all 
at the forefront of new TB drug discovery and development. Remodelling the existing 
antibacterial drug classes and structural modifications based on natural products with 
antibacterial activity are undoubtedly effective approaches to discover new antituberculosis 
agents [3-5]. Cell wall is a functional and protective interface between external and internal 
environment for every living cell. Targeting the cell wall biosynthesis has been a successful 
strategy in TB drug development. Indolcarboxamide is a novel series of antituberculosis 
agent identified recently. This series targets MmpL3, a transporter of trehalose 
monomycolate that is essential for mycobacterial cell wall biosynthesis [6]. Two other cell 
wall biosynthesis drug targets, decaprenylphosphoryl-β-D-ribose 2ʹ-epimerase (DprE1) and 
decaprenylphosphoryl-D-2-ketoerythropentose reductase (DprE2) were also identified 
recently which catalyze the epimerization of decaprenylphosphorylribose (DPR) to 
decaprenylphosphorylarabinose (DPA), a unique precursor for the synthesis of cell-wall 
arabinans [7]. DprE1, as a vulnerable tuberculosis drug target due to its cell wall localization 
and specific to mycobacteria and actinomycete, has become an attractive target for 
developing more effective and safer medicines for the treatment of drug-sensitive TB as well 
as MDR/XDR-TB [8-10]. The first DprE1 inhibitor is nitrobenzothiazinone 1 (BTZ043) 
(Figure 1) [11]. Phase I clinical trials for its next generation analogue 2 (PBTZ169) with 
improved efficacy and safety (Figure 1) have been completed [1, 12]. Compound 1 serves as 
a suicide substrate for the reduced form of DprE1 to irreversibly inactivate the enzyme by 
undergoing nitro reduction to yield a nitroso species that specifically attacks the thiol side 
chain of the active site cysteine residue, Cys387, to form a covalent adduct [13]. The 
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discovery of 1,3-benzothiazin-4-ones (BTZs), specifically 1 and its analogue 2, prompted 
further research related to the identification of potential antituberculosis agents based on 
electron deficient nitroaromatic structures. A series of potential DprE1 covalent inhibitors 
with modification on the 2 position of BTZs represented as compounds 1a and 2a was 
reported (Figure 1) [14-17]. Interestingly, two compounds with relatively minor 
modifications to the BTZs core, benzothiazinethione (SKLB-TB1001, 3) and sulfoxide of 1 
(BTZ-SO, 4), maintain potent antimycobacterial activities (Figure 1) [18, 19].  
 
Figure 1. Nitrobenzothiazinone 1 and Its Representative Derivatives. 
The crystal structures of the DprE1 with 1 and DprE1 with 2 complex as well as the 
structure-activity relationships (SARs) of this series indicated that the key constituents for 
potent activity are the sulfur atom and carbonyl group in the thiazinone ring, a strong electron 
withdrawing group (CF3, CN, NO2, etc.) in the 6 position, and more importantly a nitro group 
in the 8 position [11, 12]. However, we noticed that the nitrogen atom in the thiazinone ring 
has no direct interaction with the enzyme. Inspired by the above background information, we 
employed bioisosteric replacement strategy to replace the nitrogen atom in the 3 position with 
a carbon atom and replace the sulfur atom in the 1 position with an oxygen atom aimed to 
identify new DprE1 inhibitors with improved physicochemical properties and safety profiles. 
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Herein, we report three novel structural series, benzoxazinone 5, benzothiopyranone 6 and 
benzopyranone 7, which maintain a CF3 group at the 6 position and a NO2 group at the 8 
position (Figure 2). After further evaluation, a benzothiopyranone compound 6b as a DprE1 
inhibitor was identified as a promising preclinical candidate for the treatment of 
drug-resistant tuberculosis.  
 
Figure 2. Structures of 2 and Three Target Compound Series. 
2. Chemistry 
  The target compounds were synthesized following the procedure as outlined in Scheme 1. 
2-Chloro-3-nitro-5-(trifluoromethyl)benzamide (8) [11] was treated with oxalyl chloride 
followed by an appropriate amine to afford intermediates 9a-r. Compounds 9a-r were heated 
in DMF in the presence of K2CO3 to give benzoxazinones 5a-r after purification by column 
chromatography [20]. Benzothiopyranones 6a-r were prepared by a two-steps process. The 
key intermediate 11 was first synthesized by treating 
1-(2-chloro-3-nitro-5-(trifluoromethyl)phenyl)ethan-1-one (10) [21, 22] with NaOH and 
carbon disulfide (CS2) followed by methyl iodide (MeI) in DMSO [23]. The desired 
compounds 6a-r were obtained through nucleophilic substitution reaction of 11 with an 
appropriate amine. Due to the low reactivity of the leaving group methylthio, it was noted 
that the yield for the nucleophilic reaction between 11 and different amine could be improved 
 6 
by extending the reaction time. For the synthesis of the benzopyranone series, the key 
intermediates 13a, 13b, 13d and 13r were prepared by mixing 
3-(2-chloro-3-nitro-5-(trifluoromethyl) phenyl)-3-oxopropanoic acid (12) [24] with 
dicyclohexylcarbodiimide (DCC) followed by an appropriate amine at room temperature 
[25]. Then, the above intermediates were heated in DMF in the presence of K2CO3 to give the 
target benzopyranone compounds 7a, 7b, 7d and 7r in good yields. The structures of all new 
target compounds were characterized by 1H NMR, 13C NMR and HRMS. 
Scheme 1. Synthesis of the Target Compoundsa 
 
 
aReagents and conditions: i) oxalyl chloride, 1,2-dichloroethane, reflux, 3 h; ii) the corresponding amine, 
acetonitrile, -25 °C, 0.5-2 h, two steps, 39-95%; iii) K2CO3, DMF, 110 °C, 0.3-1 h, 20-79%; iv) CS2, NaOH, 
DMSO, 20 °C, 0.5 h; v) MeI, rt, 1 h, two steps, 60%; vi) the corresponding amine, isopropanol, 140 °C, 
12-48 h, 27-75%; vii) the corresponding amine, DCC, CH2Cl2, rt, 6-12 h, 27-60%; viii) K2CO3, DMF, 110 
°C, 1 h, 62-76%. 
3. Results and discussion  
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3.1. Identification of benzothiopyranones as a promising lead series 
  All target compounds were evaluated for their antimycobacterial activities against M. 
tuberculosis H37Rv using the microplate alamar blue assay (MABA) [26]. The minimum 
inhibitory concentration (MIC) was defined as the lowest concentration effecting a reduction 
in fluorescence of ≥ 90% relative to the mean of replicate bacterium-only controls. All target 
compounds were further tested for their cytotoxicity against mammalian cell line (Vero cells) 
as measured by the concentration required for inhibiting 50% cell growth (IC50) as compared 
to no-treatment control. Table 1 summarizes the biological data for 40 newly synthesized 
benzoxazinones, benzothiopyranones and benzopyranones. Isoniazid (INH), rifampicin 
(RFP), 1 and 2 were used as the reference compounds in these assays. 
To explore the impact of bioisosteric replacement of the core structure, the C-2 side chains 
in the first batch compounds (5a-b, 6a-b and 7a-b) were kept the same as in BTZ038 
(racemate of 1) and 2 (2-spiroketal and 2-piperazino moiety, respectively). As shown in 
Table 1, three series displayed potent in vitro antimycobacterial activities. However, their 
IC50s against Vero cell line were substantially different. When R is a spiroketal group, the 
benzoxazinone 5a and benzopyranone 7a showed equivalently potent antimycobacterial 
activities as compared to the reference compounds 1 and 2 with MICs < 0.016 μg/mL, while 
the benzothiopyranone 6a displayed less activity with a MIC 0.03 μg/mL. When R is a 
piperazino group, different level of antimycobacterial activities were observed in the 
following order: benzothiopyranone > benzoxazinone ≈ benzopyranone (6b MIC < 0.016 
μg/mL, 5b MIC 0.159 μg/mL and 7b MIC 0.116 μg/mL). It appeared that the 
benzoxazinones (5a-b) and benzopyranones (7a-b) showed a certain level of cytotoxicity 
regardless the C-2 substitution, but benzothiopyranones (6a-b) displayed lower cytotoxicity 
with IC50s > 64 μg/mL. Considering that the IC50 values of 1 and 2 are both > 64 μg/mL, this 
result indicated the importance of the sulfur atom in position 1 not only on antimycobacterial 
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activity but also toxicity. Due to the cytotoxicity concern, benzopyranone scaffold was 
dropped from further consideration.  
To further understand the structure-activity and structure-toxicity relationships (SARs and 
STRs), the R group in position 2 of the benzoxazinone and benzothiopyranone scaffolds were 
systematically investigated. The lipophilicity of the synthesized compounds was estimated 
based on their calculated ClogP values by employing ChemDraw prediction software 
(ChemDraw Professional 16.0. PerkinElmer Informatics, Inc.). A series of benzoxazinones 
(5c-r) and benzothiopyranones (6c-r) compounds was designed and synthesized. Generally, 
compounds in the benzothiopyranone series had slightly higher ClogP values as compared to 
the corresponding compounds in the benzoxazinone series (△ClogP is about 1). As 
anticipated, most benzothiopyranones exhibited more potent antimycobacterial activities than 
the corresponding benzoxazinones. This observation is consistent with the general SAR 
knowledge for the benzothiazinone class – more lipophilicity (logP) correlates with better 
antimycobacterial activity [12]. Despite their potent antimycobacterial activities, all 
benzothiopyranone compounds exhibited low cytotoxicity with IC50s > 64 μg/mL, whereas the 
benzoxazinone compounds displayed certain level of toxicity with IC50s in the range from 
3.84 to 37.85 μg/mL with the exceptions of compounds 5l and 5m. To further confirm the 
correlation between the cytotoxicity and the oxygen atom in position 1, we decided to 
re-investigate the benzopyranone series by synthesizing compounds 7d and 7r. Although 
both compounds 7d and 7r exhibited potent antimycobacterial activities, they all appeared to 
be cytotoxic with IC50 values less than 30 μg/mL. Our studies indicated that the 
benzothiopyranone series appears to have the desired antimycobacterial activities and 
cytotoxicity profiles. 
Benzothiopyranone compounds substituted with a tertiary amino R (such as 6b-g 
containing a heterocyclic amino and compounds 6p-r containing an acyclic amino group) 
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displayed potent antimycobacterial activities (MICs < 0.016 μg/mL) with the exceptions of 
compounds 6e (MIC 0.03 μg/mL) and 6g (MIC 0.054 μg/mL). However, the corresponding 
benzoxazinone compounds (5b-g and 5p-r) exhibited a wide range of MICs from 6.28 μg/mL 
to less than 0.016 μg/mL. It appears that the tertiary amino group in position 2 is better 
tolerated in the benzothiopyranone series than in the benzoxazinone series. Replacement of 
the hydrogen atom of NH in compound 6k with a methyl group resulted in a significant 
improvement of activity (6p, MIC < 0.016 μg/mL). In both the benzothiopyranone and 
benzoxazinone series, compounds with a tertiary amino R group demonstrated better 
activities than those with the corresponding secondary amino R group as exemplified by 6q 
(MIC < 0.016 μg/mL, ClogP 4.53) vs. 6n (MIC 0.902 μg/mL, ClogP 3.88), 6r (MIC < 0.016 
μg/mL, ClogP 4.80) vs. 6o (MIC 0.03 μg/mL, ClogP 4.15), 5q (MIC 0.057 μg/mL, ClogP 
3.64) vs. 5n (MIC 0.226 μg/mL, ClogP 2.98) and 5r (MIC < 0.016 μg/mL, ClogP 3.91) vs. 
5o (MIC 0.03 μg/mL, ClogP 3.25). The volume of the substituent may also be an important 
factor for antimycobacterial activity, as the lipophilicity and the size of the substituent 
increase at the same time. M. tuberculosis possesses a thick, lipid rich cell wall, which 
becomes a permeable barrier for antimicrobial agents. It has been a challenge to balance the 
lipophilicity and the antimycobacterial activity in the field of new TB drug development. The 
goal of this study is to identify a new generation of BTZs derivatives with the right balance 
between its lipophilicity (and therefore potent antimycobacterial activity) and its 
pharmacokinetic profile (and therefore better in vivo efficacy). The structure of the R group 
in position 2 has a significant influence on the physicochemical properties of the molecule as 
evidenced by the improved druggability profile of compound 2 as compared to 1 [12]. 
However, the tertiary amino R group in position 2 in the benzothiopyranone series seems to 
have a minimum influence on the antimycobacterial activities of the investigated compounds. 
It appears that there are more opportunities to identify better compounds by optimizing the 
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side chain R in position 2 of the benzothiopyranone series to deliver a potential drug 
candidate for the treatment of TB.  
Table 1. MIC, IC50 and ClogP Values of the Target Compounds 
 
Compds R ClogPa MIC
b 
(μg/mL) 
IC50 
(Vero) 
(μg/mL) 
Compds R ClogPa MIC
b 
(μg/mL) 
IC50 
(Vero) 
(μg/mL) 
5a  1.94 <0.016 9.21 6a  2.84 0.03 >64 
5b  4.60 0.159 52.14 6b  5.49 <0.016 >64 
7a 
 
2.33 <0.016 18.87 7b 
 
4.98 0.116 10.61 
5c 
 
5.12 <0.016 10.87 6c 
 
6.01 <0.016 >64 
5d 
 
4.29 6.28 25.41 6d 
 
5.18 <0.016 >64 
5e 
 
3.79 3.93 33.50 6e 
 
4.68 0.03 >64 
5f 
 
4.31 <0.016 15.59 6f 
 
5.20 <0.016 >64 
5g 
 
2.43 4.00 NDc 6g 
 
3.33 0.054 >64 
5h 
 
3.91 0.118 5.39 6h 
 
4.81 1.527 >64 
5i 
 
4.53 0.05 29.73 6i 
 
5.43 0.402 >64 
5j 
 
3.71 30.65 37.85 6j 
 
4.61 >32 >64 
5k 
 
3.33 30.54 25.36 6k 
 
4.22 >32 >64 
5l 
 
3.47 7.22 >64 6l 
 
4.37 0.206 >64 
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5m 
 
3.47 >32 >64 6m 
 
4.37 0.118 >64 
5n 
 
2.98 0.226 29.22 6n 
 
3.88 0.902 >64 
5o 
 
3.25 0.03 25.27 6o 
 
4.15 0.03 >64 
5p 
 
3.98 0.031 3.84 6p 
 
4.88 <0.016 >64 
5q 
 
3.64 0.057 9.46 6q 
 
4.53 <0.016 >64 
5r 
 
3.91 <0.016 9.27 6r 
 
4.80 <0.016 >64 
7d 
 
4.67 0.091 9.73 7r 
 
4.29 <0.016 29.39 
1   <0.016 >64 2   <0.016 >64 
INH   0.035  RFP   0.096  
aCalculated with ChemDraw Professional 16.0. bMinimum inhibitory concentration against M. tuberculosis 
H37Rv. cND, not determined. 
3.2. Evaluation of Compound 6b as a potential drug candidate for the treatment of TB 
3.2.1. Metabolic Stability and Antimycobacterial Activity against Clinical Isolates of M. 
tuberculosis of Selected Benzothiopyranones  
One significant challenge associated with the benzothiazinone series is its poor 
pharmacokinetic (PK) profile. Microsomal instability was identified as a possible liability of 
BTZs such as 2 showed medium clearance values when incubation with human or mouse 
microsomes [12]. To identify the metabolic liabilities of the novel benzothiopyranone series, 
eight compounds (6a-f, 6p and 6r) with a variety of side chain R and potent 
antimycobacterial activities together with the reference compound 2 were evaluated for their 
stability in mouse liver microsome (MLM) and human liver microsome (HLM) (Table 2). As 
shown in Table 2, compounds with relative rigid cyclic amino side chain R (6a-f) exhibited 
medium to good stability in MLM or HLM with the exception of 6d that was unstable in 
MLM. However, compounds 6p and 6r showed low microsomal stability possibly due to the 
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flexible acyclic amino side chain R. The side chain R could play a major role on influencing 
the PK profile. Further medicinal chemistry effort by increasing the size of the R group and 
therefore sterical hinderance could potentially further improve microsomal stability. 
Encouragingly, compounds 6b, 6c, 6e and 6f showed similar MLM stability as that of 2, but 
better stable than 2 in HLM.  
Table 2. Mouse and Human Liver Microsome Stability of Selected Benzothiopyranone 
Compounds 
Compds substrate remaining (%)
a 
MLMb HLMc 
6a 47.4 82.8 
6b 61.5 66.7 
6c 59.9 62.7 
6d 7.38 86.6 
6e 60.5 87.6 
6f 54.5 76.7 
6p 13.0 11.6 
6r 6.46 44.9 
2 63.9 58.7 
aSubstrate concentrations were determined in incubations with NADPH after 30 min and normalized to 
concentrations at time zero. bMouse liver microsome. cHuman liver microsome. 
Based on their good liver microsome stability, compounds 6b and 6e were further tested 
against two XDR-TB clinical isolates (Table 3). Cytotoxicity against mammalian cells was 
also evaluated against HepG2 cells. Selectivity index (SI) was subsequently calculated 
(Table 3). Inspiringly, the two new compounds together with the reference control 2 retained 
potent activities against XDR-TB strains and also displayed very low cytotoxicity with high 
IC50 values of > 64 μg/mL against HepG2 cells as compared to the reference control 2. Of 
particular interest, compound 6b exhibited potent activity against XDR-TB strains with MIC 
less than 0.002 μg/mL and excellent SI. 
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Table 3. Activity of 6b and 6e against the Selected Clinical Isolates of M. tuberculosis and 
HepG2 Cells 
Compds 
MIC (μg/mL) IC50 
(μg/mL) SI
c 
H37Rv 12611a 14231b 
6b <0.016 <0.002 <0.002 >64 >4000 
6e 0.03 0.011 0.023 >64 >2133 
2 <0.016 <0.002 <0.002 18.98 >1186 
INH 0.035 19.469 >40   
RFP 0.096 >40 >40   
aResistance to isoniazid (INH), rifampicin (RFP), streptomycin (SM), ethambutol (EMB), rifapentine 
(RFT), rifabutin (RFB) and paza-aminosalicylate (PAS). bResistance to INH, EMB, RFP, RFB, RFT, 
amikacin (AMK) and capreomycin (CPM). cSI = selectivity index, IC50/MIC. 
3.2.2. Preliminary ADME/T Studies on Compound 6b 
Based on the promising biological results described above, selected ADME/T studies were 
conducted on compound 6b to investigate its drug-like properties (Table 4). As presented in 
Table 4, compound 6b did not inhibit cytochrome P450 enzymes (CYP 1A2, CYP 2C9, CYP 
2C19, CYP 2D6 and CYP 3A4) with IC50s > 50 μM, suggesting a low potential for drug-drug 
interactions. In order to further evaluate its metabolic stability, compound 6b along with the 
reference compound 2 were investigated for their hepatocyte stability in mouse and human 
species. To our delight, compound 6b exhibited superior stability both in mouse and human 
hepatocyte with much longer t1/2 and lower intrinsic clearance (Clint) compared to the 
reference compound 2. Low inhibition of hERG (IC50 > 30 μM) suggests low risk for blocking 
the cardiac potassium channel and causing QT prolongation. A preliminary in vivo 
tolerability study was carried out in mice with a single dose at 2 g/kg. All animals survived 
after oral administration followed by a 7-day observation. Thus far, all the results supported 
compound 6b to be worth of further investigation. 
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Table 4. ADME/T Data for Compound 6b 
Assay 6b 
CYP inhibition IC50 (μM) >50 (1A2, 2C9, 2C19, 2D6, 3A4) 
Hepatocyte Stability T1/2 (min); 
Clint (µL/min/million cell)a 
462 (mouse), 224 (human); 
1.5 (mouse), 3.1 (human) 
hERG IC50 (μM) >30 
Acute Toxicity Studyb 10/10c (LD50>2 g/kg) 
aHepatocyte stability for reference compound 2: T1/2 (min) = 165 (mouse), 47.8 (human); Clint 
(µL/min/million cell) = 4.2 (mouse), 14.5 (human). bSingle oral dose in mice. cNo. of animals that 
survived/total no. of animals after 7 days.  
3.2.3. Pharmacokinetic Studies on Compound 6b 
Pharmacokinetic studies on compound 6b were performed in male Balb/c mice, following 
single oral and intravenous dose administration (Table 5). As shown in Table 5, except 
relatively low bioavailability (13.1%), compound 6b displayed an excellent PK profile as 
reflected by high plasma exposure (AUC0−∞ = 1695 ng·h/mL), and long elimination half-life (t1/2 
= 7.25 h) after oral administration. It is worth to indicate that the reference compound 2 
exhibited short half-life with t1/2 = 1.85 h when dosed at 25mg/kg in Balb/c mice as reported 
[12]. These results indicated that compound 6b had promising PK properties to move into in 
vivo efficacy studies in animal models. 
Table 5. Pharmacokinetic Parameters of Compound 6b 
Compd route dose (mg/kg) 
Cmax 
(ng/mL) 
tmax 
(h) 
t1/2a 
(h) 
AUC0-24h 
(ng·h/mL) 
AUC0-¥b 
(ng·h/mL) 
MRT0-¥c 
(h) 
clearance 
(mL/min/kg) 
Fd 
(%) 
6b po 25 588 0.5 7.25 1581 1695 6.59  13.1 
6b iv 10   6.54 4954 5184 4.91 32.3  
aPlasma elimination half-life. bPlasma exposure. cMean residence time. dBioavailability. 
3.2.4. In vivo Efficacy Study on Compound 6b in Mouse Model of TB 
Lastly, the preliminary in vivo efficacy evaluation of compound 6b was conducted in a 
murine model of acute infection with M. tuberculosis H37Rv. Compound 6b was orally 
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administered at 100 mg/kg, whereas the positive control drug isoniazid (INH) was given at 25 
mg/kg. The same formulation 0.5% carboxymethylcellulose (CMC) in water was used for all 
tested compounds. As exhibited in Table 6, compound 6b appeared highly active after 3 
weeks treatment, which resulted in a significant reduction of M. tuberculosis colony-forming 
unit (CFU) in lungs by 5.4 logs as compared to the untreated control group. Encouragingly, 
compound 6b at 100 mg/kg demonstrated similar bactericidal activity compared to INH (25 
mg/kg). Further evaluation of this promising compound is currently under way to fully assess 
its potential for further development for the treatment of MDR-TB and XDR-TB. 
Table 6. Efficacy of 6b against M. tuberculosis H37Rv infection after 3 weeks of treatment in 
Balb/c Mice 
Compds Dose (mg/kg) Log10 CFU/lung 
Untreated - 7.102±0.152 
INH 25 1.929±0.213 
6b 100 1.678±0.174 
 
3.2.5. DprE1 Inhibition Assay 
In order to confirm the inhibition of M. tuberculosis by the benzothiopyranone derivatives 
via DprE1 inhibition, we measured the inhibitory activities of the representative compounds 
6a, 6b, 6e and positive controls 1, 2 against DprE1. The results demonstrate that the selected 
benzothiopyranone compounds with potent antimycobacterial activities and diversified side 
chains displayed potent DprE1 inhibition with IC50 values from 0.63 to 4.53 µM, which 
exhibited the similar mechanism against M. tuberculosis as compared to the 
benzothiazinone controls 1 and 2 (Table 7). 
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Table 7. Inhibition on DprE1 of compounds 6a, 6b, 6e and positive controls 1, 2 
Compds IC50 DprE1 (μM) a 
6a 0.63 
6b 4.53 
6e 1.33 
1 1.03 
2 0.20 
aAll in vitro assays were performed using M. tuberculosis DprE1. 
 
4. Conclusion 
Antimycobacterial drug target DprE1 and its inhibitor benzothiazinone series represent the 
new trend in TB drug discovery. Benzothiopyranone compound 6b, obtained by scaffold 
morphing from benzothiazinones, has been identified as a promising TB drug candidate with 
potent activity, low toxicity and acceptable PK properties. Extensive SAR studies provide 
insight into the structural requirements for potent antimycobacterial activity and low 
cytotoxicity. Benzothiopyranone compounds with a tertiary amino side chain R in the 2 
position demonstrated potent activities against M. tuberculosis with low mammalian cell 
cytotoxicity. The oxygen atom in the 1 position in the benzoxazinone and benzopyranone 
series appeared to be associated with cytotoxicity. Further in vitro and in vivo studies 
indicated that the benzothiopyranone series is a promising series for further development. 
Particularly, compound 6b exhibited potent in vitro activity against M. tuberculosis H37Rv as 
well as two XDR-TB clinical isolates. This compound demonstrated excellent efficacy in 
vivo in an acute mouse model of TB by reducing bacterial load up to 5.4 log units after 3 
weeks treatment, which is equivalent to that of the first-line TB drug INH. Especially, the 
preliminary ADME/T data displayed that compound 6b owned potential druggability profiles. 
Additionally, in a PK study in mice, compound 6b exhibited a long half-life (t1/2 = 7.25 h) 
after oral administration, therefore it has the potential to be given at a lower dose and less 
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frequency to improve patient compliance. With the encouraging data, compound 6b which 
exhibits good inhibitory activity against DprE1 has been selected as a potential drug 
development candidate for the treatment of TB. Further evaluation including combination 
study and deep druggability of compound 6b is under way to fully assess its potential as a 
new agent to treat DR-TB. 
5. Experimental 
5.1. Chemistry 
5.1.1. General experimental information 
 All the solvents and chemicals were obtained from commercial sources and used without 
further purification. TLC was performed on silica gel plates (GF254) with visualization of 
components by UV light (254 nm) or exposure to I2. Column chromatography was carried out 
on silica gel (300-400 mesh). The structural identities of the prepared compounds were 
confirmed by 1H NMR and 13C NMR spectroscopy and mass spectrometry. 1H NMR spectra 
were obtained on Varian Mercury-400 at 400 MHz. 13C NMR spectra were obtained on 
Varian Mercury-400 at 100 MHz. Chemical shifts (δ) values were referenced to the residual 
solvent peak and reported in ppm and all coupling constant (J) values were given in Hz. 
CDCl3 or DMSO-d6 were used as the standard NMR solvents. The following multiplicity 
abbreviations are used: (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) multiplet, and (brs) 
broad. The chemical shifts of isomer of 13C NMR were given in parenthesis. ESI-HRMS data 
were measured on Thermo Exactive Orbitrap plus spectrometer. Melting points were 
determined on Yanaco MP-J3 microscope melting point apparatus.  
5.1.2. General procedure for the synthesis of target compounds 5a-r. To a magnetically 
stirred solution of intermediate 9 (1 mmol) in dry DMF (5 mL) was added potassium 
carbonate (138 mg, 1 mmol). The contents were heated at 110 °C for 0.3-1 h under an 
atmosphere of argon. After filtration and concentration under reduced pressure, the residue 
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was purified by flash column chromatography (EtOAc: PE = 1:4) to afford the target 
compounds 5a-r. 
5.1.2.1. 2-(2-Methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-8-nitro-6-(trifluoromethyl)-4H- 
benzo[e][1,3]oxazin-4-one (5a). Yellow solid; yield 50.3%. mp 210-212 °C. 1H NMR (400 
MHz, CDCl3) δ: 8.72 (s, 1H), 8.60 (s, 1H), 4.32-4.28 (m, 1H), 4.14-4.11 (m, 1H), 4.10-3.98 
(m, 4H), 3.51 (t, J = 8.0 Hz, 1H), 1.91-1.83 (m, 4H), 1.32 (d, J = 6.4 Hz, 3H). 13C NMR (100 
MHz, CDCl3) δ: 163.2, 155.2, 148.7, 136.3, 131.1, 127.5 (q, 2JF, C = 35 Hz), 127.0, 122.2 (q, 1JF, C 
= 271 Hz), 120.3, 106.1, 72.6 (72.5), 70.9, 43.8 (43.7), 43.0, 36.4 (35.9), 35.2 (34.7), 18.4. 
HRMS (ESI): m/z [M+H]+ calcd for C17H17F3N3O6, 416.1064; found, 416.1062. 
5.1.2.2. 2-(4-(Cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e] 
[1,3]oxazin-4-one (5b). Yellow solid; yield 51.2%. mp 194-195 °C. 1H NMR (400 MHz, 
CDCl3) δ: 8.72 (s, 1H), 8.59 (s, 1H), 4.00 (brs, 4H), 2.61 (brs, 4H), 2.26 (brs, 2H), 1.82-1.68 
(m, 5H), 1.27-1.16 (m, 4H), 0.93-0.90 (m, 2H). 13C NMR (100 MHz, CDCl3) δ: 163.2, 155.2, 
148.6, 136.3, 131.1, 127.2 (q, 2JF, C = 35 Hz), 127.1, 122.2 (q, 1JF, C = 272 Hz), 120.3, 65.2, 53.1, 
52.6, 45.4, 44.9, 35.0, 31.7, 26.7, 26.1. HRMS (ESI): m/z [M+H]+ calcd for C20H24F3N4O4, 
441.1744; found, 441.1733. 
5.1.2.3. 2-(4-(Cyclohexylmethyl)-3-methylpiperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H 
-benzo[e][1,3]oxazin-4-one (5c). Yellow solid; yield 48.4%. mp 142-144 °C. 1H NMR (400 
MHz, CDCl3) δ: 8.72 (s, 1H), 8.59 (s, 1H), 4.28-4.04 (m, 2H), 3.69-3.57 (m, 1H), 3.47-3.22 
(m, 1H), 3.01-2.89 (m, 1H), 2.62-2.32 (m, 3H), 2.09-1.99 (m, 1H), 1.89-1.85 (m, 1H), 
1.73-1.71 (m, 4H), 1.45 (brs, 1H), 1.27-1.15 (m, 3H), 1.11-1.07 (m, 3H), 0.90-0.86 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ: 163.2, 155.2, 148.7, 136.2, 131.1, 127.1 (q, 2JF, C = 35 Hz), 
126.3, 122.2 (q, 1JF, C = 272 Hz), 120.3, 60.3 (60.0), 55.0, 51.2 (50.9), 50.4 (49.3), 45.7 (45.1), 
35.6, 32.0 (31.7), 26.8, 26.2 (26.0), 15.0 (14.3). HRMS (ESI): m/z [M+H]+ calcd for 
C21H26F3N4O4, 455.1901; found, 455.1892. 
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5.1.2.4. 2-(4-(Cyclohexylmethyl)-3-oxopiperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H 
-benzo[e][1,3]oxazin-4-one (5d). Yellow solid; yield 70.4%. mp 236-238 °C. 1H NMR (400 
MHz, CDCl3) δ: 8.74-8.72 (m, 1H), 8.63-8.61 (m, 1H), 4.53 (s, 1H), 4.50 (s, 1H), 4.16-4.12 
(m, 2H), 3.59-3.57 (m, 1H), 3.53-3.51 (m, 1H), 3.34-3.31 (m, 2H), 1.73-1.65 (m, 5H), 
1.26-1.20 (m, 4H), 1.01-0.99 (m, 2H). 13C NMR (100 MHz, CDCl3) δ: 163.3 (162.9), 162.4, 
155.1 (154.6), 148.4 (148.3), 136.5 (136.3), 131.4 (131.0), 128.1 (q, 2JF, C = 35 Hz), 127.3, 
121.0 (q, 1JF, C = 272 Hz), 120.3 (120.2), 53.6 (53.5), 48.1 (47.4), 46.3 (45.8), 42.4 (42.1), 36.0 
(35.9), 30.8 (30.7), 26.2, 25.7. HRMS (ESI): m/z [M+H]+ calcd for C20H22F3N4O5, 455.1537; 
found, 455.1519. 
  5.1.2.5. 2-(4-Benzylpiperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin 
-4-one (5e). Yellow solid; yield 73.7%. mp 193-195 °C. 1H NMR (400 MHz, CDCl3) δ: 8.71 
(s, 1H), 8.58 (s, 1H), 7.36-7.29 (m, 5H), 3.96-3.94 (m, 4H), 3.59 (s, 2H), 2.62-2.60 (m, 4H). 
13C NMR (100 MHz, CDCl3) δ: 163.1, 155.3, 148.6, 137.1, 136.2, 131.1, 129.1, 128.5, 127.6, 
127.5 (q, 2JF, C = 35 Hz), 127.1, 122.2 (q, 1JF, C = 271 Hz), 120.3, 62.6, 52.4 (52.0), 45.4 (44.9). 
HRMS (ESI): m/z [M+H]+ calcd for C20H18F3N4O4, 435.1275; found, 435.1256. IR (KBr): ν 
3029, 2931, 2809, 1686, 1645, 1542, 1306, 734 cm-1. 
5.1.2.6. 2-(4-Benzyl-3-methylpiperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] 
oxazin-4-one (5f). Off-white solid; yield 24.8%. mp 152-154 °C. 1H NMR (400 MHz, CDCl3) 
δ: 8.70 (s, 1H), 8.58 (d, J = 7.6 Hz, 1H), 7.33-7.29 (m, 5H), 4.39-3.98 (m, 3H), 3.63-3.24 (m, 
3H), 2.90-2.64 (m, 2H), 2.31-2.29 (m, 1H), 1.25 (brs, 3H). 13C NMR (100 MHz, CDCl3) δ: 
163.2, 155.2, 148.6, 137.9, 136.2, 131.1 (130.9), 129.0 (128.9), 128.5, 127.6 (q, 2JF, C = 35 Hz), 
127.4, 127.1, 122.2 (q, 1JF, C = 271 Hz), 120.3, 57.8 (57.6), 54.8, 51.1 (50.9), 49.8 (48.7), 45.6 
(45.0), 15.3 (14.5). HRMS (ESI): m/z [M+H]+ calcd for C21H20F3N4O4, 449.1431; found, 
449.1422. 
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5.1.2.7. 8-Nitro-2-(4-(thiazol-2-yl)piperazin-1-yl)-6-(trifluoromethyl)-4H-benzo[e][1,3] 
oxazin-4-one (5g). Yellow solid; yield 32.2%. mp 144-145 °C. 1H NMR (400 MHz, CDCl3) δ: 
8.73 (s, 1H), 8.62 (s, 1H), 7.24 (d, J = 3.6 Hz, 1H), 6.67 (d, J = 3.6 Hz, 1H), 4.12-4.07 (m, 
4H), 3.73-3.66 (m, 4H); 13C NMR (100 MHz, CDCl3) δ: 171.2, 162.9, 155.5, 148.5, 139.7, 
136.3, 131.2, 127.9 (q, 2JF, C = 35 Hz), 127.3, 122.2 (q, 1JF, C = 272 Hz), 120.3, 108.9, 48.2 (47.9), 
44.4 (44.0). HRMS (ESI): m/z [M+H]+ calcd for C16H13F3N5O4S, 428.0635; found, 428.0632. 
  5.1.2.8. 2-(Cyclohexylamino)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin-4-one 
(5h). Off-white solid; yield 65.2%. mp 176-178 °C. 1H NMR (400 MHz, CDCl3) δ: 8.70 (s, 
1H), 8.50 (s, 1H), 6.27 (brs, 1H), 4.04-3.92 (m, 1H), 2.12-2.04 (m, 2H), 1.88-1.78 (m, 2H), 
1.70-1.62 (m, 2H), 1.49-1.34 (m, 4H). 13C NMR (100 MHz, CDCl3) δ: 163.4 (162.9), 155.8 
(157.2), 148.6 (148.4), 136.5, 130.9, 127.3 (q, 2JF, C = 35 Hz), 126.9, 122.2 (q, 1JF, C = 271 Hz), 
120.2, 52.5 (51.4), 32.6 (32.5), 25.1 (25.0), 24.6 (24.8). HRMS (ESI): m/z [M+H]+ calcd for 
C15H15F3N3O4, 358.1009; found, 358.0996. 
  5.1.2.9. 2-((Cyclohexylmethyl)amino)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin 
-4-one (5i). Yellow solid; yield 70.0%. mp 218-220 °C. 1H NMR (400 MHz, CDCl3) δ: 8.71 
(s, 1H), 8.61 (s, 0.5H), 8.52 (s, 0.5H), 3.49 (d, J = 6.8 Hz, 1H), 3.43 (t, J = 6.8 Hz, 1H), 
1.82-1.68 (m, 6H), 1.29-1.20 (m, 3H), 1.11-1.01 (m, 2H). 13C NMR (100 MHz, CDCl3) δ: 
163.2 (162.7), 158.2 (157.0), 148.6 (148.4), 136.6, 131.0 (130.8), 128.0 (127.6), 127.1 
(127.0), 122.2 (q, 1JF, C = 271 Hz), 120.6 (120.3), 48.3 (48.1), 38.3 (37.3), 30.6 (30.5), 26.2, 
25.8 (25.6). HRMS (ESI): m/z [M+H]+ calcd for C16H17F3N3O4, 372.1166; found, 372.1160. IR 
(KBr): ν 3096, 2930, 1661, 1641, 1550, 1304 cm-1. 
  5.1.2.10. 8-Nitro-2-(phenylamino)-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin-4-one (5j). 
Off-white solid; yield 66.7%. mp 255-257 °C. 1H NMR (400 MHz, CDCl3) δ: 8.92 (brs, 1H), 
8.71 (s, 1H), 8.02 (s, 1H), 7.48-7.46 (m, 4H), 7.26-7.24 (m, 1H). 13C NMR (100 MHz, CDCl3) 
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δ: 158.9, 148.7, 140.3, 137.3, 135.4, 130.9, 130.1, 129.5, 129.3 (129.2) , 128.9, 128.3, 126.2 
(q, 2JF, C = 35 Hz), 122.1 (q, 1JF, C = 271 Hz), 119.6. HRMS (ESI): m/z [M+H]+ calcd for 
C15H9F3N3O4, 352.0540; found, 352.0532. 
  5.1.2.11. 2-(Benzylamino)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin-4-one (5k). 
Yellow solid; yield 20.3%. mp 170-172 °C. 1H NMR (400 MHz, CDCl3) δ: 9.43 (brs, 1H), 
8.69 (d, J = 1.6 Hz, 1H), 8.10 (d, J = 2.0 Hz, 1H), 7.27-7.25 (m, 3H), 7.02-6.99 (m, 2H), 5.29 
(s, 2H). 13C NMR (100 MHz, CDCl3) δ: 158.9, 150.2, 140.2, 137.1,133.5, 130.1, 129.0, 128.7 
(128.6), 128.5, 127.0, 125.9 (q, 2JF, C = 36 Hz), 122.1 (q, 1JF, C = 271 Hz), 120.5, 50.2. HRMS 
(ESI): m/z [M+H]+ calcd for C16H11F3N3O4, 366.0696; found, 366.0690. 
  5.1.2.12. 2-((4-Fluorobenzyl)amino)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin 
-4-one (5l). Yellow solid; yield 54.8%. mp 174-176 °C. 1H NMR (400 MHz, DMSO-d6) δ: 
12.40 (brs, 1H), 8.57 (s, 1H), 8.48 (s, 1H), 7.23-7.22 (m, 2H), 7.12-7.08 (m, 2H), 5.00 (s, 
2H). 13C NMR (100 MHz, DMSO-d6) δ: 161.2 (J = 241 Hz), 159.6, 150.6, 139.1, 137.0, 
131.3, 131.2, 127.9, 127.8, 122.8 (q, 2JF, C = 35 Hz), 122.5 (q, 1JF, C = 271 Hz), 120.8, 114.9 (J = 
21 Hz), 49.4. HRMS (ESI): m/z [M+H]+ calcd for C16H10F4N3O4, 384.0602; found, 384.0601. 
  5.1.2.13. 2-((3-Fluorobenzyl)amino)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin 
-4-one (5m). Yellow solid; yield 26.1%. mp 208-210 °C. 1H NMR (400 MHz, DMSO-d6) δ: 
12.39 (brs, 1H), 8.59 (s, 1H), 8.49 (s, 1H), 7.35-7.30 (m, 1H), 7.13 (d, J = 10.4 Hz, 1H), 
7.09-7.04 (m, 2H), 5.00 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ: 162.1 (J = 241 Hz), 159.6, 
150.6, 139.1, 138.4, 137.1, 130.0, 127.8, 127.7, 122.7 (q, 2JF, C = 35 Hz), 122.5 (q, 1JF, C = 271 
Hz), 121.6, 120.8, 113.7 (J = 21 Hz), 112.7 (J = 23 Hz), 49.7. HRMS (ESI): m/z [M+H]+ 
calcd for C16H10F4N3O4, 384.0602; found, 384.0591. 
 5.1.2.14. 2-((3,4-Dimethoxybenzyl)amino)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] 
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oxazin-4-one (5n). Yellow solid; yield 27.0%. mp 210-212 °C. 1H NMR (400 MHz, CDCl3) δ: 
8.71-8.66 (m, 1H), 8.60-8.51 (m, 1H), 7.11-7.03 (m, 1H), 6.94-6.91 (m, 1H), 6.85-6.78 (m, 
1H), 4.72-4.65 (m, 2H), 3.88-3.82 (m, 6H). 13C NMR (100 MHz, CDCl3) δ: 163.2 (162.4), 
156.5 (157.8), 149.3 (149.2), 149.1 (148.8), 148.5 (148.3), 136.8 (136.5), 130.9 (130.6), 
129.0 (128.2), 127.8 (127.7), 127.2 (127.1), 122.2 (q, 1JF, C = 271 Hz), 120.9 (120.8), 120.3 
(120.5), 111.8 (111.5), 111.3 (111.2), 56.0, 55.9, 46.1 (45.3). HRMS (ESI): m/z [M+H]+ calcd 
for C18H15F3N3O6, 426.0908; found, 426.0891. 
5.1.2.15. 2-(((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)amino)-8-nitro-6- 
(trifluoromethyl)-4H-benzo[e][1,3]oxazin-4-one (5o). Yellow solid; yield 39.4%. mp 198-200 
°C. 1H NMR (400 MHz, DMSO-d6) δ: 9.62 (brs, 1H), 8.74-8.71 (m, 1H), 8.40-8.38 (m, 1H), 
6.91-6.89 (m, 1H), 6.86-6.79 (m, 2H), 4.40 (s, 2H), 4.20 (s, 4H). 13C NMR (100 MHz, 
DMSO-d6) δ: 162.9 (162.8), 157.1, 149.1 (148.8), 143.3, 142.8, 137.2 (136.9), 130.5 (130.4), 
128.6 (128.8), 126.6 (126.8), 124.5 (q, 2JF, C = 35 Hz), 122.7 (q, 1JF, C = 271 Hz), 120.7, 120.4, 
117.0 (117.1), 116.6, 64.1, 43.9. HRMS (ESI): m/z [M+H]+ calcd for C18H13F3N3O6, 424.0751; 
found, 424.0734. 
  5.1.2.16. 2-(Benzyl(methyl)amino)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]oxazin-4- 
one (5p). Yellow solid; yield 79.1%. mp 154-156 °C. 1H NMR (400 MHz, CDCl3) δ: 8.75 (s, 
1H), 8.59 (s, 1H), 7.39-7.34 (m, 4H), 7.31-7.29 (m, 1H), 4.93-4.91 (m, 2H), 3.29-3.27 (m, 
3H). 13C NMR (100 MHz, CDCl3) δ: 163.0, 157.1, 156.3, 148.6, 136.4, 134.4, 131.1, 129.2 
(129.0), 128.5, 127.8 (127.6), 127.0, 122.2 (q, 1JF, C = 271 Hz), 120.3 (120.2), 53.6 (53.2), 36.5 
(34.4). HRMS (ESI): m/z [M+H]+ calcd for C17H13F3N3O4, 380.0853; found, 380.0842. IR 
(KBr): ν 3092, 2944, 1683, 1639, 1544, 1313, 736 cm-1. 
5.1.2.17. 2-((3,4-Dimethoxybenzyl)(methyl)amino)-8-nitro-6-(trifluoromethyl)-4H-benzo 
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[e][1,3]oxazin-4-one (5q). Yellow solid; yield 45.7%. mp 142-144 °C. 1H NMR (400 MHz, 
CDCl3) δ: 8.75 (s, 1H), 8.59 (s, 1H), 6.97-6.91 (m, 1H), 6.86-6.83 (m, 2H), 4.85-4.82 (m, 
2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.30-3.26 (m, 3H). 13C NMR (100 MHz, CDCl3) δ: 163.1, 
156.9 (156.2), 149.3, 148.6, 136.4, 131.1, 128.2, 127.1, 126.9, 122.2 (q, 1JF, C = 271 Hz), 121.4, 
120.3 (120.2), 111.8, 111.4, 111.1 (111.0), 56.0, 55.9, 53.5 (53.1), 36.4 (34.2). HRMS (ESI): 
m/z [M+H]+ calcd for C19H17F3N3O6, 440.1064; found, 440.1049. 
5.1.2.18. 2-(((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)(methyl)amino)-8-nitro-6- 
(trifluoromethyl)-4H-benzo[e][1,3]oxazin-4-one (5r). Yellow solid; yield 57.2%. mp 69-71 
°C. 1H NMR (400 MHz, CDCl3) δ: 8.71 (s, 1H), 8.59 (s, 1H), 6.87-6.77 (m, 3H), 4.80 (s, 1H), 
4.78 (s, 1H), 4.24 (s, 4H), 3.25 (d, J = 2.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ: 163.1, 
156.9 (156.1), 148.7, 143.8, 143.7, 136.3, 130.9, 127.6 (127.5), 127.1, 122.2 (q, 1JF, C = 271 
Hz), 121.6, 121.0, 120.3 (120.2), 117.8 (117.6), 117.3 (116.7), 64.3, 53.0 (52.6), 36.1 (34.2). 
HRMS (ESI): m/z [M+H]+ calcd for C19H15F3N3O6, 438.0908; found, 438.0902. IR (KBr): ν 
3067, 2986, 1706, 1636, 1545, 1311, 887 cm-1. 
5.1.3. General procedure for the synthesis of target compounds 6a-r. A 15 mL capped tube 
was charged with intermediate 11 (64 mg，0.2 mmol) and corresponding amine (1.0 mmol). 
The degassed isopropanol (5 mL) was added. The tube was flushed with argon, capped, and 
heated at 140 °C for 12-48 h. After cooling to room temperature, the reaction mixture was 
concentrated in vacuum, and the residue was purified by column chromatography (EtOAc: 
PE = 1:2) to give the target compounds 6a-r. 
5.1.3.1. 2-(2-Methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-8-nitro-6-(trifluoromethyl)-4H- 
thiochromen-4-one (6a). Yellow solid; yield 54.7%. mp 165-167 °C. 1H NMR (400 MHz, 
CDCl3) δ: 9.13 (s, 1H), 8.77 (s, 1H), 6.45 (s, 1H), 4.29-4.26 (m, 1H), 4.14-4.09 (m, 1H), 
3.84-3.81 (m, 4H), 3.53-3.48 (m, 1H), 1.91-1.85 (m, 4H), 1.32 (d, J = 6.0 Hz, 3H). 13C NMR 
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(100 MHz, CDCl3) δ: 176.9, 156.0, 144.4, 134.0, 133.5, 131.4, 128.9 (q, 2JF, C = 35 Hz), 125.3, 
122.7 (q, 1JF, C = 267 Hz), 106.2, 100.2, 72.5, 70.9, 46.5, 36.0 (34.8), 18.4. HRMS (ESI): m/z 
[M+H]+ calcd for C18H18F3N2O5S, 431.0890; found, 431.0879. 
5.1.3.2. 2-(4-(Cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H- 
thiochromen-4-one (6b). Orange solid; yield 69.6%. mp 184-186 °C. 1H NMR (400 MHz, 
CDCl3) δ: 9.12 (d, J = 2.0 Hz, 1H), 8.75 (d, J = 2.0 Hz, 1H), 6.25 (s, 1H), 3.66 (brs, 4H), 2.56 
(brs, 4H), 2.20-2.19 (m, 2H), 1.80-1.68 (m, 5H), 1.51 (brs, 1H), 1.27-1.16 (m, 3H), 0.94-0.85 
(m, 2H). 13C NMR (100 MHz, CDCl3) δ: 176.9, 159.6, 144.4, 134.0, 133.7, 131.5, 128.9 (q, 2JF, 
C = 35 Hz), 125.3, 122.6 (q, 1JF, C = 271 Hz), 100.2, 65.1, 52.7, 48.0, 35.0, 31.7, 26.7, 26.1. 
HRMS (ESI): m/z [M+H]+ calcd for C21H25F3N3O3S, 456.1563; found, 456.1544. IR (KBr): ν 
3033, 2926, 1638, 1595, 1548, 1296 cm-1. 
5.1.3.3. 2-(4-(Cyclohexylmethyl)-3-methylpiperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H- 
thiochromen-4-one (6c). Yellow solid; yield 58.4%. mp 162-164 °C. 1H NMR (400 MHz, 
CDCl3) δ: 9.12 (s, 1H), 8.74 (s, 1H), 6.24 (s, 1H), 3.80-3.77 (m, 2H), 3.47 (brs, 1H), 3.19 
(brs, 1H), 2.98-2.95 (m, 1H), 2.58-2.48 (m, 2H), 2.36 (brs, 1H), 2.02-1.99 (m, 1H), 1.89-1.85 
(m, 1H), 1.74-1.68 (m, 4H), 1.46 (brs, 1H), 1.25-1.11 (m, 6H), 0.91-0.88 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ: 176.8, 159.4, 144.4, 133.9, 133.7, 131.5, 128.9 (q, 2JF, C = 35 Hz), 125.3, 
122.6 (q, 1JF, C = 271 Hz), 99.8, 60.2, 55.1, 54.2, 50.0, 48.2, 35.6, 32.0 (31.7), 26.7, 26.2 (26.0), 
15.3. HRMS (ESI): m/z [M+H]+ calcd for C22H27F3N3O3S, 470.1720; found, 470.1707. 
5.1.3.4. 1-(Cyclohexylmethyl)-4-(8-nitro-4-oxo-6-(trifluoromethyl)-4H-thiochromen-2-yl) 
piperazin-2-one (6d). Orange solid; yield 63.8%. mp 217-219 °C. 1H NMR (400 MHz, 
CDCl3) δ: 9.14 (s, 1H), 8.79 (s, 1H), 6.18 (s, 1H), 4.24 (brs, 2H), 3.91-3.89 (m, 2H), 
3.61-3.58 (m, 2H), 3.36-3.34 (m, 2H), 1.73-1.66 (m, 6H), 1.26-1.21 (m, 3H), 1.03-0.99 (m, 
2H). 13C NMR (100 MHz, CDCl3) δ: 176.5, 163.4, 157.6, 144.3, 133.6, 133.4, 131.8, 129.3 (q, 
2JF, C = 35 Hz), 125.5, 122.5 (q, 1JF, C = 272 Hz), 100.2, 53.5, 50.7, 46.0, 44.8, 36.0, 30.8, 26.2, 
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25.7. HRMS (ESI): m/z [M+H]+ calcd for C21H23F3N3O4S, 470.1356; found, 470.1344. IR 
(KBr): ν 3084, 2923, 1652, 1637, 1590, 1548, 1446, 1297 cm-1. 
5.1.3.5. 2-(4-Benzylpiperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one (6e). 
Yellow solid; yield 62.2%. mp 188-190 °C. 1H NMR (400 MHz, CDCl3) δ: 9.12 (s, 1H), 8.75 
(s, 1H), 7.35-7.26 (m, 5H), 6.24 (s, 1H), 3.68 (brs, 4H), 3.60 (s, 2H), 2.63 (brs, 4H). 13C NMR 
(100 MHz, CDCl3) δ: 176.9, 159.6, 144.4, 137.0, 134.0, 133.6, 131.5, 129.1, 128.8, 128.5, 
127.6, 125.4, 122.6 (q, 1JF, C = 271 Hz), 110.4, 62.6, 52.1, 47.9. HRMS (ESI): m/z [M+H]+ 
calcd for C21H19F3N3O3S, 450.1094; found, 450.1076. 
5.1.3.6. 2-(4-Benzyl-3-methylpiperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-thiochromen 
-4-one (6f). Yellow solid; yield 50.8%. mp 183-185 °C. 1H NMR (400 MHz, CDCl3) δ: 9.12 
(s, 1H), 8.75 (s, 1H), 7.35-7.26 (m, 5H), 6.23 (s, 1H), 4.06 (d, J = 13.2 Hz, 1H), 3.84 (t, J = 
15.2 Hz, 2H), 3.40 (t, J = 9.6 Hz, 1H), 3.27-3.20 (m, 2H), 2.85 (d, J = 12.4 Hz, 1H), 2.71 
(brs, 1H), 2.32 (t, J = 9.2 Hz, 1H), 1.26 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ: 
176.8, 159.3, 144.4, 137.8, 133.9, 133.6, 131.5, 129.0, 128.9 (q, 2JF, C = 35 Hz), 128.5, 127.4, 
125.3, 122.6 (q, 1JF, C = 271 Hz), 100.0, 57.7, 54.8, 54.2, 49.4, 48.1, 15.5. HRMS (ESI): m/z 
[M+H]+ calcd for C20H21F3N3O3S, 464.1250; found, 464.1228. IR (KBr): ν 3077, 2971, 1634, 
1587, 1538, 1299, 737 cm-1. 
5.1.3.7. 8-Nitro-2-(4-(thiazol-2-yl)piperazin-1-yl)-6-(trifluoromethyl)-4H-thiochromen 
-4-one (6g). Yellow solid; yield 38.1%. mp 243-245 °C. 1H NMR (400 MHz, CDCl3) δ: 9.14 
(s, 1H), 8.80 (s, 1H), 7.28 (d, J = 3.6 Hz, 1H), 6.70 (d, J = 3.6 Hz, 1H), 6.31 (s, 1H), 
3.86-3.81 (m, 8H). 13C NMR (100 MHz, CDCl3) δ: 177.1, 171.0, 159.4, 144.4, 139.4, 133.8, 
133.5, 131.7, 129.2 (q, 2JF, C = 35 Hz), 125.5, 122.5 (q, 1JF, C = 271 Hz), 108.7, 101.3, 47.7, 47.2. 
HRMS (ESI): m/z [M+H]+ calcd for C17H14F3N4O3S2, 443.0454; found, 443.0455. 
5.1.3.8. 2-(Cyclohexylamino)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one (6h). 
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Yellow solid; yield 40.5%. mp 247-249 °C. 1H NMR (400 MHz, CDCl3) δ: 9.15 (d, J = 2.0 
Hz, 1H), 8.78 (d, J = 2.0 Hz, 1H), 6.37 (s, 1H), 3.59 (s, 1H), 2.14-2.11 (m, 2H), 1.86-1.82 (m, 
2H), 1.72-1.68 (m, 2H), 1.45-1.38 (m, 4H). 13C NMR (100 MHz, CDCl3) δ: 175.3, 158.6, 
143.9, 134.2, 133.6, 131.6, 129.0, 125.2, 122.6 (q, 1JF, C = 271 Hz), 98.2, 53.8, 32.3, 25.2, 24.6. 
HRMS (ESI): m/z [M+H]+ calcd for C16H16F3N2O3S, 373.0828; found, 373.0824. 
5.1.3.9. 2-((Cyclohexylmethyl)amino)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one 
(6i). Yellow solid; yield 59.7%. mp 220-222 °C. 1H NMR (400 MHz, CDCl3) δ: 9.14 (d, J = 
1.6 Hz, 1H), 8.77 (d, J = 1.6 Hz, 1H), 6.14 (s, 1H), 5.39 (brs, 1H), 3.20 (t, J = 6.4 Hz, 2H), 
1.84-1.68 (m, 5H), 1.30-1.21 (m, 4H), 1.05-1.01 (m, 2H). 13C NMR (100 MHz, CDCl3) δ: 
176.4, 158.6, 143.8, 134.5, 134.2, 131.8, 128.7, 125.2, 122.6 (q, 1JF, C = 271 Hz), 97.9, 50.7, 
37.1, 30.9, 26.2, 25.6. HRMS (ESI): m/z [M+H]+ calcd for C17H18F3N2O3S, 387.0985; found, 
387.0974. 
5.1.3.10. 8-Nitro-2-(phenylamino)-6-(trifluoromethyl)-4H-thiochromen-4-one (6j). Yellow 
solid; yield 57.3%. mp 244-246 °C. 1H NMR (400 MHz, DMSO-d6) δ: 10.27 (brs, 1H), 8.84 
(s, 2H), 7.50-7.46 (m, 2H), 7.35-7.27 (m, 3H), 6.22 (s, 1H). 13C NMR (100 MHz, DMSO-d6) 
δ: 175.4, 157.3, 144.6, 137.6, 134.9, 133.4, 129.8, 129.6, 126.7 (q, 2JF, C = 34 Hz), 126.2, 
125.5, 123.9, 122.8 (q, 1JF, C = 271 Hz), 98.3. HRMS (ESI): m/z [M+H]+ calcd for C16H10F3N2O3S, 
367.0359; found, 367.0371. 
5.1.3.11. 2-(Benzylamino)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one (6k). Yellow 
solid; yield 57.9%. mp 187-189 °C. 1H NMR (400 MHz, CDCl3) δ: 9.13 (d, J = 2.0 Hz, 1H), 
8.77 (d, J = 2.0 Hz, 1H), 7.40-7.34 (m, 5H), 6.17 (s, 1H), 4.50 (d, J = 5.2 Hz, 2H). 13C NMR 
(100 MHz, CDCl3) δ: 176.7, 157.7, 143.8, 135.2, 134.4, 134.0, 131.9, 129.3, 129.1, 128.7, 
127.8, 125.4, 122.6 (q, 1JF, C = 271 Hz), 98.6, 48.6. HRMS (ESI): m/z [M+H]+ calcd for 
C17H12F3N2O3S, 381.0515; found, 381.0522. 
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5.1.3.12. 2-((4-Fluorobenzyl)amino)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one 
(6l). Yellow solid; yield 75.3%. mp 207-209 °C. 1H NMR (400 MHz, CDCl3) δ: 9.14 (s, 1H), 
8.79 (s, 1H), 7.35 (t, J = 6.4 Hz, 2H), 7.10 (t, J = 6.8 Hz, 2H), 6.21 (s, 1H), 5.51 (brs, 1H), 
4.50 (d, J = 2.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ: 176.7, 162.8 (J = 247 Hz), 157.7, 
143.9, 134.3, 133.9, 131.9, 131.0, 129.7 (J = 8 Hz), 129.0 (q, 2JF, C = 35 Hz), 125.4, 122.6 (q, 1JF, 
C = 271 Hz), 116.3 (J = 22 Hz), 98.7, 47.8. HRMS (ESI): m/z [M+H]+ calcd for C17H11F4N2O3S, 
399.0421; found, 399.0414. 
5.1.3.13. 2-((3-Fluorobenzyl)amino)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one 
(6m). Yellow solid; yield 50.2%. mp 173-175 °C. 1H NMR (400 MHz, CDCl3) δ: 9.13 (d, J = 
2.0 Hz, 1H), 8.80 (d, J = 2.0 Hz, 1H), 7.39-7.35 (m, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.06 (d, J 
= 8.0 Hz, 2H), 6.16 (s, 1H), 4.55-4.53 (m, 2H). 13C NMR (100 MHz, CDCl3) δ: 176.7, 163.2 
(J = 247 Hz), 157.8, 143.9, 137.7, 134.3, 133.9, 131.9, 130.9 (J = 8 Hz), 129.0 (q, 2JF, C = 35 
Hz), 125.5, 123.1, 122.6 (q, 1JF, C = 271 Hz), 115.6 (J = 21 Hz), 114.5 (J = 22 Hz), 98.9, 47.9. 
HRMS (ESI): m/z [M+H]+ calcd for C17H11F4N2O3S, 399.0421; found, 399.0408. 
5.1.3.14. 2-((3,4-Dimethoxybenzyl)amino)-8-nitro-6-(trifluoromethyl)-4H-thiochromen 
-4-one (6n). Yellow solid; yield 56.8%. mp 193-195 °C. 1H NMR (400 MHz, CDCl3) δ: 9.14 
(d, J = 1.6 Hz, 1H), 8.79 (d, J = 2.0 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.91 (d, J = 1.6 Hz, 
1H), 6.86 (d, J = 8.0 Hz, 1H), 6.45 (s, 1H), 4.50 (s, 2H), 3.90 (s, 3H), 3.88 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ: 175.2, 159.8, 149.5, 149.3, 143.9, 134.1, 133.4, 131.7, 129.1 (q, 2JF, C = 
35 Hz), 127.2, 125.4, 122.5 (q, 1JF, C = 271 Hz), 120.7, 111.4, 111.2, 98.7, 56.0, 55.9, 48.6. 
HRMS (ESI): m/z [M+H]+ calcd for C19H16F3N2O5S, 441.0727; found, 441.0743. 
5.1.3.15. 2-(((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)amino)-8-nitro-6- 
(trifluoromethyl)-4H-thiochromen-4-one (6o). Yellow solid; yield 27.2%. mp 198-200 °C. 1H 
NMR (400 MHz, CDCl3) δ: 9.14 (d, J = 1.6 Hz, 1H), 8.79 (d, J = 1.6 Hz, 1H), 6.89-6.86 (m, 
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3H), 6.50 (s, 1H), 4.46 (s, 2H), 4.25 (s, 4H). 13C NMR (100 MHz, CDCl3) δ: 144.0, 143.9, 
143.8, 134.2, 133.7, 131.8, 131.7, 129.0 (q, 2JF, C = 35 Hz), 128.1, 125.4, 125.3, 122.6 (q, 1JF, C = 
273 Hz), 120.9, 118.0, 116.8, 98.7, 64.3, 48.1. HRMS (ESI): m/z [M+H]+ calcd for 
C19H14F3N2O5S, 439.0570; found, 439.0571. IR (KBr): ν 3081, 2988, 1633, 1585, 1552, 1296, 
890 cm-1. 
5.1.3.16. 2-(Benzyl(methyl)amino)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one (6p). 
Yellow solid; yield 39.3%. mp 142-144 °C. 1H NMR (400 MHz, CDCl3) δ: 9.17 (d, J = 2.4 
Hz, 1H), 8.77-8.76 (m, 1H), 7.40–7.34 (m, 4H), 7.26–7.24 (m, 1H), 6.26 (s, 1H), 4.85 (s, 2H), 
3.26 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 176.2, 159.4, 144.3, 134.5, 133.7, 133.6, 131.6, 
129.2, 128.7 (q, 2JF, C = 35 Hz), 128.4, 126.8, 125.3, 122.6 (q, 1JF, C = 271 Hz), 99.2, 56.6, 39.5. 
HRMS (ESI): m/z [M+H]+ calcd for C18H14F3N2O3S, 395.0672; found, 395.0671. 
5.1.3.17. 2-((3,4-Dimethoxybenzyl)(methyl)amino)-8-nitro-6-(trifluoromethyl)-4H- 
thiochromen-4-one (6q). Yellow solid; yield 59.5%. mp 186-188 °C. 1H NMR (400 MHz, 
CDCl3) δ: 9.17 (s, 1H), 8.76 (s, 1H), 6.86 (d, J = 6.4 Hz, 1H), 6.79 (d, J = 6.4 Hz, 1H), 6.76 
(s, 1H), 6.23 (s, 1H), 4.77 (s, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.23 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ: 176.3, 159.2, 149.6, 149.1, 144.3, 133.8, 133.7, 131.6, 129.0 (q, 2JF, C = 35 
Hz), 126.9, 125.2, 122.6 (q, 1JF, C = 271 Hz), 119.4, 111.5, 110.2, 99.2, 56.3, 56.0, 55.9, 39.3. 
HRMS (ESI): m/z [M+H]+ calcd for C20H18F3N2O5S, 455.0883; found, 455.0878. 
5.1.3.18. 2-(((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)(methyl)amino)-8-nitro-6- 
(trifluoromethyl)-4H-thiochromen-4-one (6r). Yellow solid; yield 55.3%. mp 200-202 °C. 1H 
NMR (400 MHz, CDCl3) δ: 9.16 (s, 1H), 8.76 (s, 1H), 6.86 (d, J = 6.4 Hz, 1H), 6.74-6.71 (m, 
2H), 6.20 (s, 1H), 4.72 (s, 2H), 4.25 (s, 4H), 3.22 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 
176.2, 159.2, 144.3, 144.0, 143.6, 133.8, 133.7, 131.5, 128.6 (q, 2JF, C = 35 Hz), 127.6, 125.2, 
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122.6 (q, 1JF, C = 271 Hz), 120.0, 118.0, 115.8, 99.2, 64.4, 64.3, 56.0, 39.3. HRMS (ESI): m/z 
[M+H]+ calcd for C20H16F3N2O5S, 453.0727; found, 453.0697. 
5.1.4. General procedure for the synthesis of target compounds 7a, 7b, 7d, 7r. To a 
magnetically stirred solution of intermediate 13 (0.2 mmol) in dry DMF (2 mL) was added 
potassium carbonate (28 mg, 0.2 mmol). The contents were heated at 110 °C for 1 h under an 
atmosphere of argon. After filtration and concentration under reduced pressure, the residue 
was purified by flash column chromatography (MeOH:CH2Cl2 = 1:100) to afford the target 
compounds 7a, 7b, 7d, 7r. 
5.1.4.1. 2-(2-Methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-8-nitro-6-(trifluoromethyl)-4H- 
chromen-4-one (7a). Yellow solid; yield 72.5%. mp 197-199 °C. 1H NMR (400 MHz, CDCl3) 
δ: 8.74 (s, 1H), 8.51 (s, 1H), 5.66 (s, 1H), 4.32-4.27 (m, 1H), 4.14-4.10 (m, 1H), 3.77-3.71 
(m, 4H), 3.53-3.49 (m, 1H), 1.88-1.85 (m, 4H), 1.31 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ: 173.0, 161.4, 147.9, 137.2, 129.0, 126.8 (q, 2JF, C = 35 Hz), 126.0, 125.5, 122.5 (q, 1JF, 
C = 271 Hz), 106.1, 86.9, 72.5, 70.9, 43.8 (43.7), 35.9 (34.7), 18.4. HRMS (ESI): m/z [M+H]+ 
calcd for C18H18F3N2O6, 415.1112; found, 415.1114. IR (KBr): ν 3072, 2977, 1656, 1611, 1543, 
1325 cm-1. 
5.1.4.2. 2-(4-(Cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-chromen-4 
-one (7b). Yellow solid; yield 61.5%. mp 229-231 °C. 1H NMR (400 MHz, CDCl3) δ: 8.74 (d, 
J = 2.0 Hz, 1H), 8.50 (d, J = 2.0 Hz, 1H), 5.59 (s, 1H), 3.65 (brs, 4H), 2.55 (brs, 4H), 
2.20-2.19 (m, 2H), 1.80-1.62 (m, 5H), 1.28-1.19 (m, 4H), 0.91-0.86 (m, 2H). 13C NMR (100 
MHz, CDCl3) δ: 172.9, 161.7, 147.8, 137.3, 129.0, 126.6, 126.1, 125.4, 122.5 (q, 1JF, C = 272 
Hz), 86.8, 65.2, 52.6, 45.3, 35.0, 31.7, 26.7, 26.1. HRMS (ESI): m/z [M+H]+ calcd for 
C21H25F3N3O4, 440.1792; found, 440.1792. IR (KBr): ν 3063, 2922, 1664, 1615, 1532, 1324 
cm-1. 
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5.1.4.3. 1-(Cyclohexylmethyl)-4-(8-nitro-4-oxo-6-(trifluoromethyl)-4H-chromen-2-yl) 
piperazin-2-one (7d). Yellow solid; yield 66.1%. mp 134-136 °C. 1H NMR (400 MHz, CDCl3) 
δ: 8.76 (d, J = 2.0 Hz, 1H), 8.55 (d, J = 2.0 Hz, 1H), 5.54 (s, 1H), 4.14 (s, 2H), 3.98-3.96 (m, 
2H), 3.58-3.56 (m, 2H), 3.34 (d, J = 7.2 Hz, 2H), 1.77-1.66 (m, 5H), 1.29-1.19 (m, 4H), 
1.02-0.99 (m, 2H). 13C NMR (100 MHz, CDCl3) δ: 172.8, 163.1, 160.5, 147.7, 137.3, 129.3, 
127.2 (q, 2JF, C = 35 Hz), 126.0, 125.8, 122.4 (q, 1JF, C = 271 Hz), 87.1, 53.6, 48.1, 46.2, 42.1, 
36.0, 30.8, 26.2, 25.7. HRMS (ESI): m/z [M+H]+ calcd for C21H23F3N3O5, 454.1584; found, 
454.1583. 
5.1.4.4. 2-(((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)(methyl)amino)-8-nitro-6- 
(trifluoromethyl)-4H-chromen-4-one (7r). Yellow solid; yield 76.2%. mp 159-161 °C. 1H 
NMR (400 MHz, CDCl3) δ: 8.76 (d, J = 2.4 Hz, 1H), 8.51 (d, J = 2.4 Hz, 1H), 6.86-6.84 (m, 
1H), 6.76-6.72 (m, 2H), 5.61 (s, 1H), 4.66 (s, 2H), 4.25 (s, 4H), 3.13 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ: 172.6, 162.2, 147.8, 143.9, 143.6, 137.3, 129.1, 127.8, 126.9 (q, 2JF, C = 35 
Hz), 126.0, 125.4, 122.5 (q, 1JF, C = 271 Hz), 120.5, 117.9, 116.2, 86.6, 64.4, 64.3, 53.4, 36.2. 
HRMS (ESI): m/z [M+H]+ calcd for C20H16F3N2O6, 437.0955; found, 437.0946. 
5.1.5. General procedure for the synthesis of intermediates 9a-r. To a magnetically stirred 
solution of 2-chloro-5-(trifluoromethyl)-3-nitrobenzamide (8, prepared according to the 
reported method [11]) (1.07 g, 4.0 mmol) in dry 1,2-dichloroethane (10 mL) was added 
oxalyl chloride (863 mg, 6.8 mmol). The mixture was heated to reflux for 3 h under an 
atmosphere of argon. The solvent was evaporated under reduced pressure. The residue was 
dissolved in acetonitrile (15 mL) and then cooled to -25 °C. Corresponding amine (4.0 mmol) 
in acetonitrile (5 mL) was slowly added to the above solution keeping the reaction under -25 
°C for 0.5-2 h. The precipitated solid was filtered, washed with cooled acetonitrile and dried. 
The crude product was purified by silica gel column chromatography (EtOAc : PE = 1:2) to 
obtain the intermediates 9a-r. 
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5.1.5.1. N-(2-Chloro-3-nitro-5-(trifluoromethyl)benzoyl)-2-methyl-1,4-dioxa-8-azaspiro 
[4.5]decane-8-carboxamide (9a). Yellow solid; yield 77.2%. mp 115-117 °C. 1H NMR (400 
MHz, CDCl3) δ: 8.12 (s, 1H), 7.81 (s, 1H), 4.26-4.22 (m, 1H), 4.08-4.05 (m, 1H), 3.63-3.55 
(m, 4H), 3.47-3.43 (m, 1H), 1.78-1.74 (m, 4H), 1.27 (d, J = 6.0 Hz, 3H). 
5.1.5.2. N-(2-Chloro-3-nitro-5-(trifluoromethyl)benzoyl)-4-(cyclohexylmethyl)piperazine-1 
-carboxamide (9b). Yellow solid; yield 61.8%. mp 105-107 °C. 1H NMR (400 MHz, CDCl3) δ: 
8.14 (s, 1H), 7.84 (s, 1H), 3.55 (brs, 4H), 2.47 (brs, 4H), 2.21 (brs, 2H), 1.81-1.71 (m, 5H), 
1.28-1.20 (m, 4H), 0.91-0.89 (m, 2H).  
5.1.5.3. N-(2-Chloro-3-nitro-5-(trifluoromethyl)benzoyl)-4-(cyclohexylmethyl)-3- 
methylpiperazine-1- carboxamide (9c). Yellow solid; yield 46.9%. mp 120-122 °C. 1H NMR 
(400 MHz, CDCl3) δ: 9.17 (brs, 1H), 8.14 (s, 1H), 7.82 (s, 1H), 3.69-3.66 (m, 2H), 3.30 (brs, 
1H), 3.00 (brs, 1H), 2.87-2.84 (m, 1H), 2.45-2.43 (m, 2H), 2.20 (brs, 1H), 1.98-1.94 (m, 1H), 
1.86-1.83 (m, 1H), 1.72-1.66 (m, 5H), 1.43 (brs, 1H), 1.19-1.17 (m, 2H), 1.03-1.02 (m, 3H), 
0.88-0.83 (m, 2H).  
5.1.5.4. N-(2-Chloro-3-nitro-5-(trifluoromethyl)benzoyl)-4-(cyclohexylmethyl)-3- 
oxopiperazine-1-carboxamide (9d). Yellow solid; yield 38.7%. mp 103-105 °C. 1H NMR (400 
MHz, CDCl3) δ: 9.73 (brs, 1H), 8.13 (s, 1H), 7.87 (s, 1H), 4.29 (brs, 2H), 3.75 (brs, 2H), 3.42 
(brs, 2H), 3.25-3.24 (m, 2H), 1.71-1.61 (m, 5H), 1.26-1.18 (m, 4H), 0.96-0.94 (m, 2H).  
  5.1.5.5. 4-Benzyl-N-(2-chloro-3-nitro-5-(trifluoromethyl)benzoyl)piperazine-1- 
carboxamide (9e). Yellow solid; yield 69.0%. mp 157-158 °C. 1H NMR (400 MHz, CDCl3) δ: 
9.27 (brs, 1H), 8.13 (s, 1H), 7.81 (s, 1H), 7.31-7.26 (m, 5H), 3.54 (brs, 6H), 2.49 (brs, 4H). 
5.1.5.6. 4-Benzyl-N-(2-chloro-3-nitro-5-(trifluoromethyl)benzoyl)-3-methylpiperazine-1- 
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carboxamide (9f). Yellow solid; yield 59.8%. mp 108-110 °C. 1H NMR (400 MHz, CDCl3) δ: 
9.05 (brs, 1H), 8.13 (s, 1H), 7.81 (s, 1H), 7.33-7.26 (m, 5H), 4.05-4.01 (m, 1H), 3.75-3.67 (m, 
2H), 3.24-3.21 (m, 2H), 3.06 (brs, 1H), 2.77-2.74 (m, 1H), 2.56 (brs, 1H), 2.18 (brs, 1H), 
1.18 (brs, 3H).  
5.1.5.7. N-(2-Chloro-3-nitro-5-(trifluoromethyl)benzoyl)-4-(thiazol-2-yl)piperazine-1- 
carboxamide (9g). Yellow solid; yield 68.3%. mp 180-182 °C. 1H NMR (400 MHz, CDCl3) δ: 
9.18 (brs, 1H), 8.16 (s, 1H), 7.86 (s, 1H), 7.22 (d, J = 3.6 Hz, 1H), 6.66 (d, J = 3.6 Hz, 1H), 
3.70 (brs, 4H), 3.62 (brs, 4H). 
  5.1.5.8. 2-Chloro-N-(cyclohexylcarbamoyl)-3-nitro-5-(trifluoromethyl)benzamide (9h). 
Yellow solid; yield 65.5%. mp 168-170 °C. 1H NMR (400 MHz, CDCl3) δ: 10.98 (brs, 1H), 
8.22 (d, J = 7.6 Hz, 1H), 8.15 (s, 1H), 7.99 (s, 1H), 3.48-3.47 (m, 1H), 1.83-1.80 (m, 2H), 
1.72-1.69 (m, 2H), 1.62-1.59 (m, 1H), 1.32-1.19 (m, 5H).  
  5.1.5.9. 2-Chloro-N-((cyclohexylmethyl)carbamoyl)-3-nitro-5-(trifluoromethyl)benzamide 
(9i). Yellow solid; yield 88.3%. mp 158-160 °C. 1H NMR (400 MHz, CDCl3) δ: 10.96 (brs, 
1H), 8.34 (brs, 1H), 8.15 (s, 1H), 8.00 (s, 1H), 3.02 (t, J = 6.4 Hz, 2H), 1.74-1.66 (m, 5H), 
1.49-1.39 (m, 1H), 1.27-1.13 (m, 3H), 0.93-0.84 (m, 2H). 
  5.1.5.10. 2-Chloro-3-nitro-N-(phenylcarbamoyl)-5-(trifluoromethyl)benzamide (9j). Yellow 
solid; yield 41.2%. mp 199-201 °C. 1H NMR (400 MHz, CDCl3) δ: 10.72 (brs, 1H), 10.32 
(brs, 1H), 8.21 (s, 1H), 8.02 (s, 1H), 7.30-7.27 (m, 4H), 7.19-7.15 (m, 1H).  
  5.1.5.11. N-(Benzylcarbamoyl)-2-chloro-3-nitro-5-(trifluoromethyl)benzamide (9k). Yellow 
solid; yield 68.3%. mp 151-153 °C. 1H NMR (400 MHz, CDCl3) δ: 10.63 (brs, 1H), 8.64 (brs, 
1H), 8.12 (s, 1H), 8.00 (s, 1H), 7.36-7.30 (m, 3H), 7.22-7.19 (m, 2H), 4.42-4.38 (m, 2H). 
 33 
  5.1.5.12. 2-Chloro-N-((4-fluorobenzyl)carbamoyl)-3-nitro-5-(trifluoromethyl)benzamide 
(9l). Yellow solid; yield 94.7%. mp 190-191 °C. 1H NMR (400 MHz, CDCl3) δ: 10.40 (brs, 
1H), 8.62 (brs, 1H), 8.14 (s, 1H), 8.01 (s, 1H), 7.20 (brs, 2H), 7.02 (brs, 2H), 4.38 (s, 2H). 
  5.1.5.13. 2-Chloro-N-((3-fluorobenzyl)carbamoyl)-3-nitro-5-(trifluoromethyl)benzamide 
(9m). Yellow solid; yield 85.8%. mp 204-205 °C. 1H NMR (400 MHz, CDCl3) δ: 10.33 (brs, 
1H), 8.68 (brs, 1H), 8.14 (s, 1H), 8.01 (s, 1H), 7.33-7.26 (m, 1H), 7.02-6.92 (m, 3H), 4.41 (d, 
J = 6.0 Hz, 2H).  
  5.1.5.14. 2-Chloro-N-((3,4-dimethoxybenzyl)carbamoyl)-3-nitro-5-(trifluoromethyl) 
benzamide (9n). Yellow solid; yield 82.3%. mp 61-62 °C. 1H NMR (400 MHz, CDCl3) δ: 
10.47 (brs, 1H), 8.57 (brs, 1H), 8.14 (s, 1H), 8.02 (s, 1H), 6.83-6.76 (m, 3H), 4.33 (d, J = 5.6 
Hz, 2H), 3.88 (s, 6H). 
5.1.5.15. 2-Chloro-N-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)carbamoyl)-3-nitro-5- 
(trifluoromethyl)benzamide (9o). Yellow solid; yield 48.9%. mp 155-156 °C. 1H NMR (400 
MHz, CDCl3) δ: 10.97 (brs, 1H), 8.60 (brs, 1H), 8.16 (s, 1H), 8.01 (s, 1H), 6.80 (d, J = 8.4 
Hz, 1H), 6.68-6.65 (m, 2H), 4.25 (s, 2H), 4.23 (s, 4H).  
  5.1.5.16. N-(Benzyl(methyl)carbamoyl)-2-chloro-3-nitro-5-(trifluoromethyl)benzamide 
(9p). Yellow solid; yield 90.1%. mp 129-131 °C. 1H NMR (400 MHz, CDCl3) δ: 9.30 (brs, 
1H), 8.13 (s, 1H), 7.77 (s, 1H), 7.35-7.31 (m, 4H), 7.21-7.20 (m, 1H), 4.53 (s, 2H), 3.01 (s, 
3H). 
5.1.5.17. 2-Chloro-N-((3,4-dimethoxybenzyl)(methyl)carbamoyl)-3-nitro-5- 
(trifluoromethyl)benzamide (9q). Yellow solid; yield 54.3%. solid. mp 70-72 °C. 1H NMR 
(400 MHz, CDCl3) δ: 8.36 (brs, 1H), 8.16 (s, 1H), 7.81 (s, 1H), 6.84 (d, J = 8.0 Hz, 1H), 
6.79-6,76 (m, 2H), 4.45 (s, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 3.02 (s, 3H). 
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5.1.5.18. 2-Chloro-N-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)(methyl)carbamoyl) 
-3-nitro-5-(trifluoromethyl)benzamide (9r). Yellow solid; yield 76.0%. mp 156-158 °C. 1H 
NMR (400 MHz, CDCl3) δ: 8.47 (brs, 1H), 8.15 (s, 1H), 7.80 (s, 1H), 6.85 (d, J = 8.0 Hz, 
1H), 6.73 (s, 1H), 6.69 (d, J = 8.0 Hz, 1H), 4.41 (s, 2H), 4.26 (s, 4H), 3.01 (s, 3H).  
5.1.6. Synthesis of the 2-(methylthio)-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one 
(11). To a magnetically stirred solution of NaOH (800 mg，20 mmol) in DMSO (5 mL) was 
added CS2 (2.34 g，30 mmol) and intermediate 10 (prepared according to the reported 
method [21, 22]) (2.67 g，10 mmol) in turn, keeping the reaction solution under 20 °C for 30 
min. CH3I (10 mmol) was then added to the reaction mixture. The contents were stirred at 
room temperature for 1 h. The reaction was quenched by H2O (50 mL) and the mixture was 
extracted with EtOAc (3 × 50 mL). The combined extracts were washed with brine, dried 
over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was 
purified by column chromatography (EtOAc:PE = 1:4) to obtain the target compound 11. 
Yellow solid; yield 60.0%. mp 146-148 °C. 1H NMR (400 MHz, CDCl3) δ: 9.12 (d, J = 2.0 
Hz, 1H), 8.84 (d, J = 2.0 Hz, 1H), 6.91 (s, 1H), 2.70 (s, 3H). 
5.1.7. General procedure for the synthesis of intermediates 13a, 13b, 13d, 13r. To a 
magnetically stirred solution of intermediate 12 (prepared according to the reported method 
[24]) (312 mg, 1.0 mmol) in dry dichloromethane (5 mL) was added 
dicyclohexylcarbodiimide (DCC) (201 mg, 1.0 mmol). The contents were stirred at room 
temperature for 30 min under an atmosphere of argon. Corresponding amine (1.0 mmol) was 
then added to the reaction solution. The reaction mixture was stirred at room temperature for 
6-12 h. After filtration, the filtrate was concentrated under reduced pressure. The residue was 
purified by column chromatography (EtOAc:PE = 1:10) to give the intermediates 13a, 13b, 
13d, 13r. 
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5.1.7.1. 3-(2-Chloro-3-nitro-5-(trifluoromethyl)phenyl)-3-hydroxy-1-(2-methyl-1,4-dioxa-8 
-azaspiro[4.5]decan-8-yl)prop-2-en-1-one (13a). Yellow solid; yield 55.5%. mp 108-110 °C. 
1H NMR (400 MHz, CDCl3) δ: 15.64 (brs, 1H), 8.01 (s, 1H), 8.00 (s, 1H), 5.72 (s, 1H), 
4.30-4.13 (m, 1H), 4.12-4.08 (m, 1H), 3.75-3.47 (m, 5H), 1.79-1.75 (m, 4H), 1.31-1.29 (m, 
3H). 
5.1.7.2. 3-(2-Chloro-3-nitro-5-(trifluoromethyl)phenyl)-1-(4-(cyclohexylmethyl)piperazin 
-1-yl)-3-hydroxyprop-2-en-1-one (13b). Yellow solid; yield 57.1%. mp 105-107 °C. 1H NMR 
(400 MHz, CDCl3) δ: 15.62 (brs, 1H), 8.01 (s, 1H), 8.00 (s, 1H), 5.67 (s, 1H), 3.73-3.49 (m, 
4H), 2.45 (m, 4H), 2.17 (brs, 2H), 1.79-1.71 (m, 5H), 1.26-1.20 (m, 4H), 0.90-0.87 (m, 2H). 
5.1.7.3. 4-(3-(2-Chloro-3-nitro-5-(trifluoromethyl)phenyl)-3-hydroxyacryloyl)-1- 
(cyclohexylmethyl)piperazin-2-one (13d). Yellow solid; yield 26.5%. mp 146-148 °C. 1H 
NMR (400 MHz, CDCl3) δ: 15.1 (brs, 1H), 8.04 (s, 1H), 7.99 (s, 1H), 5.64 (s, 1H), 4.16-4.12 
(m, 2H), 3.93-3.90 (m, 2H), 3.47-3.42 (m, 2H), 3.30-3.28 (m, 2H), 1.73-1.64 (m, 5H), 
1.26-1.13 (m, 4H), 1.00-0.97 (m, 2H).  
5.1.7.4. 3-(2-Chloro-3-nitro-5-(trifluoromethyl)phenyl)-N-((2,3-dihydrobenzo[b][1,4] 
dioxin-6-yl)methyl)-3- hydroxy-N-methylacrylamide (13r). Yellow solid; yield 60.3%. mp 
150-152 °C. 1H NMR (400 MHz, CDCl3) δ: 15.57 (brs, 1H), 8.02 (s, 2H), 6.86-6.69 (m, 3H), 
5.72-5.70 (m, 1H), 4.57-4.44 (m, 2H), 4.26-4.24 (m, 4H), 3.07-2.96 (m, 3H).  
5.2. Biological evaluation 
5.2.1. Minimum inhibitory concentration assay (MIC). MICs against replicating M. 
tuberculosis were determined by the microplate alamar blue assay (MABA) [26]. RFP, INH, 
1 and 2 were included as positive controls. Compound stock solutions and the range of final 
testing concentrations were 32 to 0.5 μg/mL, respectively. For the most active compounds, 
the stock concentration and final testing concentration range were lowered to 3.2 μg/mL and 
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2 to 0.002 μg/mL, respectively. M. tuberculosis H37Rv or clinical isolates were grown to late 
log phase (70 to 100 Klett units) in Difco Middlebrook 7H9 Broth (Seebio) supplemented 
with 0.2% (vol/vol) glycerol, 0.05% Tween 80, and 10% (vol/vol) albumin-dextrose-catalase 
(Seebio) (7H9-ADC-TG). Cultures were centrifuged, washed twice, and then re-suspended in 
phosphate-buffered saline. Suspensions were then passed through an 8 μm-pore-size filter to 
remove clumps, and aliquots were frozen at -80 °C. Twofold dilutions of compounds were 
prepared in 7H9-ADC-TG in a volume of 100 μL in 96-well clear-bottom microplates (BD). 
M. tuberculosis (100 μL containing 2 × 105 CFU) was added to yield a final testing volume of 
200 μL. The plates were incubated at 37 °C; on day 7 of incubation, 12.5 μL of 20% Tween 
80 and 20 μL of alamar blue were added to all wells. After incubation at 37 °C for 16 to 24 h, 
the fluorescence was read at an excitation of 530 nm and an emission of 590 nm. The MIC 
was defined as the lowest concentration effecting a reduction in fluorescence of ≥ 90% 
relative to the mean of replicate bacterium-only controls. 
5.2.2. Cytotoxicity assay. Vero cells and HepG2 cells were cultured in RPMI1640 medium 
supplemented with 10% fetal bovine serum (FBS). The cells were incubated in a humidified 
atmosphere of 5% CO2 at 37 °C. Stocks of cells were cultured in 25-cm2 tissue culture flasks 
and subcultured two to three times per week. Cytotoxicity testing was performed in a 
transparent 96-well microplate. Outer perimeter wells were filled with sterile water to prevent 
dehydration in experimental wells. The cells were incubated at 37 °C under 5% CO2 until 
confluent and then diluted with culture medium to 4 × 105 cells/mL. Threefold serial dilutions 
of the stock solutions resulted in final concentrations of 64 to 0.26 μg/mL in a final volume of 
100 μL. After incubation at 37 °C for 48 h, the medium was removed, and the monolayers 
were washed twice with 100 μL of warm Hanks balanced salt solution (HBSS). Warm 
medium (100 μL) and 10 μL of freshly made methyl-thiazolyldiphenyl-tetrazolium bromide 
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(MTT) were added to each well, and then the plates were incubated for 4 h, after which the 
absorbance was determined at 492 nm. 
5.2.3. Liver microsome stability assay. The assay was performed with liver microsomes 
from male CD-1 mouse (Xenotech) and pooled human (Bioreclamation). Compounds of 
interest were tested at 1 μM with a final concentration of microsomal protein of 1 mg/mL. 
The reaction was initiated by the addition of NADPH (1 mM), and samples were incubated 
for up to 60 min at 37 °C in a shaking incubator. The reaction was terminated at 0, 5, 15 and 
30 min by the addition of ice-cold ACN/MeOH (50:50) spiked with internal standard. An 
aliquot of reaction mixture was removed at 0, 5, 15, 30, and 60 min, respectively, followed by 
addition of ice-cold ACN/MeOH (50:50, v/v) spiked with internal standard. Samples were 
centrifuged at 4,000 rpm at 4 °C for 15 min and the supernatants were analysed by 
LC-MS/MS. The assay evaluated the metabolic stability of compounds by measuring the 
amount of parent remaining to test compounds with or without NADPH cofactor. 
5.2.4. In vitro CYP inhibition. Briefly, compound 6b was incubated with human liver 
microsome (0.2 mg/mL) and CYP enzyme (1A2, 2C9, 2C19, 2D6 and 3A4) for 20 min. The 
compound was tested at a range of concentrations (0.1-50 µM), alongside a relevant positive 
control. The positive controls, which are CYP isoform-specific substrates were also incubated 
with human liver microsomes at a range of test compound concentrations (0.1-50 μM). At the 
end of the incubation, the amount of parent remaining to each substrate is monitored by 
LC-MS/MS at each of the test compound concentrations. IC50 was then determined based on 
the measurements.  
5.2.5. Hepatocyte stability assay. The assay was performed with hepatocytes from pooled 
male CD-1 mouse (Bioreclamation IVT) and pooled human (Bioreclamation IVT). 
Compounds of interest (6b and 2) were tested at 1 µM with a final hepatocyte concentration 
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of 1 million cells/mL. The reaction was initiated by addition of pre-warmed hepatocyte 
working solution (2 million cells/mL) to the compound working solution (2 µM). Reaction 
mixtures were incubated for up to 120 min at 37 °C in a CO2 incubator at ~ 100 rpm. At the 
pre-determined time points (0, 15, 30, 60, 90 and 120 min), 30 µL of the reaction mixtures 
was removed and reaction was terminated by addition of 200 µL ice-cold ACN/MeOH (50:50) 
spiked with internal standard. Samples were mixed well and then were centrifuged at 4,000 
rpm at 4 °C for 15 min. Supernatants were removed and were analysed by LC-MS/MS. The 
assay evaluated the metabolic stability of compounds in hepatocytes by measuring amount of 
parent remaining of the test compounds. 
5.2.6. Inhibition Evaluation on hERG K+ Channel. The electrophysiology recording of 
hERG channel current was carried out following the standard protocol as described 
previously [27]. HEK 293 cells were stably transfected with human Ether-à-go-go related 
gene (hERG) channel. The voltage-gated hERG potassium channel current was recorded at 
room temperature (25 °C) from randomly selected transfected cells under whole-cell manual 
patch clamp systems equipped with EPC10 USB (HEKA) or Multiclamp 700B amplifier 
(Molecular Devices), while electrical data was digitalized by Digidata1440A with sampling 
frequency at 10 kHz using Patchmaster or pClamp10 respectively. hERG current inhibition in 
presence of 5 concentrations, including 30, 10, 3.0, 1.0 and 0.3 µM, was tested for IC50 
determination. Dofetilide was also included as a positive control to ensure the accuracy and 
sensitivity of the test system. All experiments were performed in duplicate for IC50 
determination. The compound with IC50 > 30 μM was generally considered to have a lower 
potential for hERG K+ channel inhibition. 
5.2.7. Acute toxicity study. Compound 6b was screened in vivo with a single dose in Balb/c 
mouse (female) weighing 18 to 21 g with ten mice. The number of mice which survived after 
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an oral administration of a single dose at 2 g/kg, followed by a 7-day observation, was 
recorded. 
5.2.8. Pharmacokinetic studies in mice. All animal protocols were approved by Institute 
Animal Care and Use Committee. The selected compound 6b was subjected to 
pharmacokinetic studies in Balb/c mouse (male) weighing 22 to 23 g with three mice in oral 
administration group and three mice in intravenous injection group. The tested compound 
was formulated at a concentration of 2.5 mg/mL for a dose of 25 mg/kg given orally (p.o.) 
and at 2.0 mg/mL for a dose of 10 mg/kg given intravenously (i.v.). The tested compound was 
formulated with 0.5% carboxymethyl cellulose and 0.5% Tween 80 for p.o. administration 
and with 20% HP-β-CD with 4 mol/L HCl for i.v. administration. Blood samples were 
collected at 5, 15, 30 min, 1, 2, 4, 7, 24 h after oral dosing and i.v. administration. Plasma was 
harvested and stored at -80 °C until analysed. Plasma samples were extracted with 
acetonitrile containing terfenadine as an internal standard using a 20:1 extractant-to-plasma 
ratio. Analyte quantitation was performed by a LC/TSQ Quantum Access mass spectrometer 
(AB Sciex 5500). Chromatographic separation was performed on a Kinetex C18 100A 
column (30 mm × 3 mm, 2.6 μm) with an isocratic mobile phase of acetonitrile/water (80:20, 
v/v) containing 0.1% formic acid at 0.8 mL/min flow rate. Compound detection on the mass 
spectrometer was performed in electrospray positive ionization mode. The selected reaction 
monitoring transition was m/z 456.17/359.80. The pharmacokinetic parameters were 
calculated using WinNonlin software version 6.3 based on non-compartmental analysis 
(Pharsight Corporation, Mountain View, USA). The oral bioavailability was calculated as the 
ratio between the area under the curve (AUC) following intravenous administration corrected 
for dose (F = (AUCp.o. × dosei.v.)/(AUCi.v. × dosep.o.)). 
5.2.9. In vivo TB infection assay. SPF Balb/c mice (female) weighing 18−20 g were used in 
this study. Each treated group was composed of 6 mice. Mice were infected via aerosol with a 
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suspension of 5 × 106 CFU/mL M. tuberculosis (H37Rv) using a Glas-Col inhalation system, to 
deposit 50−100 bacilli into the lungs of each animal. The course of infection was followed by 
plating homogenates of harvested organs [n = 3] on 7H11 agar plates (7H11 plates containing 
10% oleic acid-albumin-dextrose-catalase (OADC) enrichment and 50 μg/mL cycloheximide, 
200 U/mL polymyxin B, 50 μg/mL carbenicillin, and 20 μg/mL trimethoprim) and 
determining CFU on days 3, 10, and 30 post infection. INH and compound 6b were dissolved 
or suspended in 0.5% CMC and administered by oral gavage in a maximum volume of 200 
μL such that a dose of 25 and 100 mg/kg body weight was achieved. The control group was 
received only 0.5% CMC. Mice were began to treat on days 10 post infection and 5 times per 
week. The treatment period was 3 weeks. Mice were sacrificed the day after the last day of 
treatment, lungs removed, homogenized, and serially diluted in 10-fold steps in HBSS. One 
hundred μL were spread on 7H11 agar in duplicate. The plates were incubated at 37 °C for 3 
weeks. Data are expressed as the log10 (and as log10 reduction) provided by a given dose of the 
compound against the growth of the organism in the untreated control group. Mean log10 
values were calculated from bacterial burden counts. Student’s t test was used to compare 
means between the test and control groups. A P value of ≤0.05 was considered significant. 
5.2.10. In vitro DprE1 inhibition assay. DprE1 assays were performed as described 
previously [28]. Briefly, a 10 μL reaction was performed at 30 C in 384-well black plates in 
buffer containing 50 mM Hepes, pH 7.5, 100 mM NaCl, 1.5% (v/v) DMSO, 100 μM 
Tween-20, 2 μM FAD, and 50 μM resazurin, with variable concentrations of FPR and DprE1. 
Reactions were monitored by following an increase in fluorescence intensity (λex = 530 nm, 
λem = 595 nm) associated with the formation of resorufin. For inhibition studies, DprE1 (1 
μM) was measured with the resazurin assay with 1 mM FPR in the presence of different 
inhibitor concentrations. The IC50 values were obtained by plotting the initial velocities with 
inhibitor concentration. The IC50 values calculated using the software program GraphPad 
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Prism. 
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